Neurovance Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Neurovance Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013493
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurovance Inc (Neurovance) is a clinical stage neuroscience focused company that develops centanafadine (CTN) SR for adult and pediatric Attention Deficit Hyperactivity Disorder (ADHD). CTN, formerly EB-1020, is a novel triple reuptake inhibitor that acts as a functional hybrid with activity intermediate between stimulants and non-stimulants; and increases dopamine activity. ADHD is the common childhood disorders that has three subtypes – hyperactive-impulsive; inattentive and combined hyperactive-impulsive and inattentive. The company received funds from various investors that include Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, and State of Wisconsin Investment Board (SWIB). Neurovance is headquartered in Cambridge, Massachusetts, the US.

Neurovance Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurovance Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Neurovance Acquires EB-1020 Program from Euthymics Bioscience 10
Venture Financing 11
Neurovance Raises USD0.6 Million in Venture Financing 11
Neurovance Raises Additional USD1.5 Million in Venture Financing 12
Neurovance Raises Additional USD5 Million Financing 13
Neurovance Raises USD1 Million in Financing Round 14
Neurovance Raises Additional USD5.5 Million in Venture Financing 15
Neurovance Raises Additional USD4 Million in Venture Financing 16
Neurovance Raises US$3.3 Million In Extended Series A1 Financing 17
Neurovance Raises USD3 Million in Venture Financing 18
Neurovance Raises US$6 Million In Series A1 Financing 19
Neurovance Raises Additional US$0.32 Million In Venture Financing 21
Acquisition 22
Otsuka Pharma to Acquire Neurovance 22
Neurovance Inc – Key Competitors 23
Neurovance Inc – Key Employees 24
Neurovance Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Dec 14, 2016: Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Neurovance Inc, Pharmaceuticals & Healthcare, Key Facts 2
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurovance Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurovance Acquires EB-1020 Program from Euthymics Bioscience 10
Neurovance Raises USD0.6 Million in Venture Financing 11
Neurovance Raises Additional USD1.5 Million in Venture Financing 12
Neurovance Raises Additional USD5 Million Financing 13
Neurovance Raises USD1 Million in Financing Round 14
Neurovance Raises Additional USD5.5 Million in Venture Financing 15
Neurovance Raises Additional USD4 Million in Venture Financing 16
Neurovance Raises US$3.3 Million In Extended Series A1 Financing 17
Neurovance Raises USD3 Million in Venture Financing 18
Neurovance Raises US$6 Million In Series A1 Financing 19
Neurovance Raises Additional US$0.32 Million In Venture Financing 21
Otsuka Pharma to Acquire Neurovance 22
Neurovance Inc, Key Competitors 23
Neurovance Inc, Key Employees 24

★海外企業調査レポート[Neurovance Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Whiting Petroleum Corporation:企業の戦略・SWOT・財務分析
    Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Mastek Ltd (MASTEK):企業の財務・戦略的SWOT分析
    Mastek Ltd (MASTEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • IGas Energy PLC (IGAS):企業の財務・戦略的SWOT分析
    IGas Energy PLC (IGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • International Seaways Inc (INSW):石油・ガス:M&Aディール及び事業提携情報
    Summary International Seaways Inc (INSW) owns and operates a fleet of oceangoing vessels involved in the transportation of crude oil and petroleum products. The company holds ownership in LNG (liquefied natural gas) carriers and FSO (floating storage and offloading) service vessels. It charters the …
  • BRF SA:企業のM&A・事業提携・投資動向
    BRF SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BRF SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Inivata Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in …
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • National Industrialization Co (2060):企業の財務・戦略的SWOT分析
    National Industrialization Co (2060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • LiNiu Technology Group:企業の戦略・SWOT・財務分析
    LiNiu Technology Group - Strategy, SWOT and Corporate Finance Report Summary LiNiu Technology Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Tampa Electric Co:企業の戦略的SWOT分析
    Tampa Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Strong Petrochemical Holdings Ltd:企業の戦略・SWOT・財務情報
    Strong Petrochemical Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Strong Petrochemical Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Saline Water Conversion Corp:企業の戦略的SWOT分析
    Saline Water Conversion Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Cytokinetics Inc (CYTK)-製薬・医療分野:企業M&A・提携分析
    Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases, which compromise muscle performance. The company’s lead drug candidate, tirasemtiv, a fast skeletal muscle troponin activa …
  • Tourism Holdings Limited:企業の戦略・SWOT・財務分析
    Tourism Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Tourism Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kiwibank Limited:企業の戦略・SWOT・財務情報
    Kiwibank Limited - Strategy, SWOT and Corporate Finance Report Summary Kiwibank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dermalogica Inc:企業の戦略・SWOT・財務情報
    Dermalogica Inc - Strategy, SWOT and Corporate Finance Report Summary Dermalogica Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Schmolz + Bickenbach AG:企業の戦略・SWOT・財務情報
    Schmolz + Bickenbach AG - Strategy, SWOT and Corporate Finance Report Summary Schmolz + Bickenbach AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • LumiraDx Ltd (LMDX):企業の財務・戦略的SWOT分析
    LumiraDx Ltd (LMDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sangoma Technologies Corp (STC):企業の財務・戦略的SWOT分析
    Sangoma Technologies Corp (STC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆